Cell/Gene Tx channel feed

As­traZeneca’s Alex­ion inks AAV cap­sid deal with JCR Phar­ma

5 hours ago
R&D

'CRISPR Cures' cen­ter launch­es with $20M to make cus­tomized gene edit­ing ther­a­pies

20 hours ago
R&D

Shell com­pa­ny Con­cen­tra has found its rhythm, with Car­go Ther­a­peu­tics as its lat­est buy­out tar­get

Yesterday
Deals

Sin­ga­pore­an biotech gets Chi­na thumbs-up for study of po­ten­tial­ly cu­ra­tive HBV cell ther­a­py

Yesterday
R&D
China

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Last week
R&D
In Focus

CEOs push EU to in­clude cell, gene ther­a­py in­cen­tives in Biotech Act

Last week
Law

Bay­er's stem cell group Blue­Rock re­struc­tures pipeline, lays off staffers

2 weeks ago
People

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

2 weeks ago
FDA+

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

3 weeks ago
R&D

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

3 weeks ago
FDA+

BioN­Tech stops mak­ing cell ther­a­py at Mary­land site af­ter drop­ping germ cell tu­mor in­di­ca­tion

3 weeks ago
R&D
Manufacturing

Gilead, Ar­cel­lx con­tin­ue to spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py

4 weeks ago
R&D

Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

4 weeks ago
R&D

Gene ther­a­py biotech Splice­Bio gets $135M short­ly af­ter start­ing first clin­i­cal tri­al

4 weeks ago
Financing
Startups

Ver­tex lays off 125 work­ers af­ter type 1 di­a­betes cell ther­a­py failed study in March

4 weeks ago
People
Pharma

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Last month
FDA+

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

Last month
FDA+

Re­genxbio says Duchenne gene ther­a­py im­proved mo­tor skills in five pa­tients

Last month
R&D

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Last month
FDA+

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Last month
R&D

Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

Last month
R&D

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Last month
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

Last month
R&D

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

Last month
Startups
Deals
1234 Next page Last page
A service from the Financial Times